Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader–Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 Compass PWS Study

Clinical Therapeutics · Published 2026-07-01 · DOI 10.1016/j.clinthera.2026.06.019

Free full text

Authors (10)

Elizabeth Roof, Theresa V. Strong, Diane E.J. Stafford, Deepan Singh, Sani M. Roy, Dilesh Doshi, Yang Zhang, Alana Salvucci, James M. Youakim, Shawn E. McCandless

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Roof, E., Strong, T., Stafford, D., et al. (2026). Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader–Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 Compass PWS Study. Clinical Therapeutics. https://doi.org/10.1016/j.clinthera.2026.06.019

Related articles

• Mycotoxin Trends of Cannabis Compliance Testing in Cannabis Flower and Concentrates in the United States · Clinical Therapeutics · 2026 · Same journal
• Early-Onset Cannabis Use, Retinal Biomarkers, and Risk for Schizophrenia Preliminary Study · Clinical Therapeutics · 2026 · Same journal
• Novel Therapeutic Treatments in Perinatal Genetics Bridging Prenatal and Postnatal Care of Genetic Conditions · Clinical Therapeutics · 2026 · Same journal
• Implications of TLR4 Polymorphisms for Precision Therapeutics in Gram-negative Infections: An Ethnogeographic-Stratified Meta-Analysis · Clinical Therapeutics · 2026 · Same journal
• Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitors in NSCLC: Insights From Pharmacovigilance Data, a Retrospective Case-control Study, and Single-cell RNA Sequencing Dataset · Clinical Therapeutics · 2026 · Same journal
• Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research · Clinical Therapeutics · 2026 · Same journal
• Benefits of Medical Cannabis in Patients With Pain Registered in the Minnesota Medical Cannabis Program · Clinical Therapeutics · 2026 · Same journal
• A Simultaneous Assessment of Efficacy and Safety of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease · Clinical Therapeutics · 2026 · Same journal
• Comment on “Effect of Remimazolam or Propofol Combined With Esketamine on Anesthesia and Early Perioperative Neurocognitive Disorders in Patients Undergoing Thoracoscopic Partial Lung Resection: A Randomized Clinical Trial” · Clinical Therapeutics · 2026 · Same journal
• Prenatal Diagnosis and Novel Therapeutics in Treatment of Genetic Conditions: Challenges and Opportunities · Clinical Therapeutics · 2026 · Same journal